Related Experiment Videos
Thrombus deposition on polyurethanes designed for biomedical applications
H D Wabers1, R W Hergenrother, A J Coury
1Department of Chemical Engineering, University of Wisconsin, Madison 53706.
Journal of Applied Biomaterials : an Official Journal of the Society for Biomaterials
|October 1, 1992
Summary
Biomaterials like polyurethanes were tested for blood compatibility. Certain polyurethanes, including ether-free and Pellethane 2363-80A, showed low platelet and fibrinogen deposition, indicating potential for biomedical uses.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Hemocompatibility Studies
Background:
- Polyurethanes are widely used in biomedical devices.
- Assessing their thrombogenicity is crucial for clinical success.
- Understanding surface properties influences blood-material interactions.
Purpose of the Study:
- To evaluate the thrombogenicity of six polyurethanes using an ex-vivo canine shunt model.
- To compare commercial and laboratory-synthesized polyurethanes, including ether-free variants.
- To investigate the impact of surface characterization techniques and cleaning methods on thrombogenicity.
Main Methods:
- Ex-vivo canine shunt model with 111In-platelet and 125I-fibrinogen deposition measurements.
- Surface characterization using static and dynamic contact angle measurements and ESCA.
- Acetone extraction to remove extrusion waxes from Pellethane 2363-80A.
Main Results:
- Low deposition of platelets and fibrinogen was observed on ether-free polyurethanes.
- Pellethane 2363-80A also demonstrated relatively nonthrombogenic surface properties.
- Surface characterization provided insights into material properties influencing hemocompatibility.
Conclusions:
- Ether-free polyurethanes exhibit promising nonthrombogenic characteristics.
- Pellethane 2363-80A is a suitable candidate for biomedical applications due to its hemocompatibility.
- These polyurethanes warrant further investigation for use in blood-contacting medical devices.